top of page
DidierLeconteHR Vertical_edited.jpg

Montreal, QC, May 2, 2024  – Morphocell Technologies is thrilled to announce the appointment of Didier Leconte as an independent member of its Board of Directors, effective immediately.

PBedford Headshot.jpg

Montreal, QC, April 22, 2024 – Morphocell Technologies is proud to announce the appointment of Patrick Bedford as our new Vice President of Regulatory Affairs.


Laval, QC, April 4, 2024 - Morphocell Technologies proudly announces the closure of a US$40 million Series A financing round. This significant financial milestone, led by Genson Capital, is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial.


Montreal, QC, January 17, 2024 – Morphocell Technologies is thrilled to announce the appointment of Dr. Calley Hirsch as its new Vice President Preclinical Development


Montreal, QC, July 24, 2023 – Morphocell Technologies is excited to announce the appointment of Dr. Panos Chrysanthopoulos as its new Chief Development Officer


Morphocell will present its progress, platform and preclinical data at Biotech Showcase 2023, one of the most important investor conferences, in San Francisco, CA.

cover2_iPSC-derived hepatocyte-like cells_CK18-DAPI.png

Morphocell Technologies announces the publication of an innovative, scalable method for generating high-quality liver cells from induced pluripotent stem cells. 


The US Patent Office (USPTO) has granted Morphocell Technologies patent number US11096388 covering the use of its Encapsulated Liver Tissue as part of a Bioartificial Liver Device


Morphocell Technologies, CQDM and Takeda Pharmaceutical Company Limited, with support from the Stem Cell Network, came together to fund a $979,200 Quantum Leap project that will enable Morphocell to generate preclinical efficacy and safety data in large animals for ReLiver®ELT


Morphocell has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.


Morphocell Technologies’ quest to transform the treatment of liver disease took another major step forward today with the announcement of new Stem Cell Network  (SCN) funding for the Paganelli lab at Le Centre hospitalier universitaire Sainte-Justine. 

Bennilover 2020 image.jpg

The Morphocell team is gearing up for a busy and exciting 2020, starting with our participation at two can’t-miss conferences.


Stem cell commercialization expert Dr. Jennifer Moody appointed Chief Operating Officer beginning October 7th, 2019.


Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.


Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.


Morphocell Technologies signs exclusive license for the commercialisation of innovative stem cell-derived Encapsulated Liver Tissue technology.

bottom of page